Consulting & communication ►

Consulting & communication ▼

▪ Strategic and global drug developm(...)

▪ Communication

Pre-clinical studies ►

Pre-clinical studies ▼

▪ Overview

▪ Pilot and proof of concept studies

▪ Ocular efficacy studies

Clinical trials ►

Clinical trials ▼

▪ Overview

▪ Phase I

▪ Phase II - III

▪ Audits

▪ Patient and Investigator recruitme(...)

▪ Project management

▪ Medical writing

R&D support services ►

R&D support services ▼

▪ Animal model development

▪ Ocular histopathology

Iris Pharma is a global company specialized in ocular drug development (including preclinical research, biomedical research and bioanalysis). Iris Pharma has already gained the trust of the largest pharmaceutical laboratories and of the most up-to-date biotechnology companies.

Our basic Research Department creates and validates new in vivo models which can be used to select a lead compound for ophthalmic use, for proof of concept studies and to evaluate of the efficacy of ocular drugs.

• development of new animal models according to the specific requirements of our clients
• improvement of existing models
• exploring new animal models. Different models related to diabetic retinopathy or glaucoma are currently under development.

Recently, the Iris Pharma Research Team has validated several animal models for investigating the various aspects of Age-related Macular Degeneration (AMD) and retinal degeneration: corneal angiogenesis (suture model on rabbits), retinopathy of prematurity (ROP, hyperoxia model in pup mice), chemical burn (alcohol, sodium hydroxide models in rats, mice and rabbits), retinal vascular permeability (VEGF-induced leakage in rabbits), and choroidal neovascularization model (CNV using argon laser in rats).